Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
TAK-243 by Millennium Pharmaceuticals for Lymphoma: Likelihood of Approval
TAK-243 is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I...